



MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, March 17, 2016
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Bryan Larson, PharmD
Clinton Sheffield, MD
Clayton Grace, RPh
Susan Siegfried, MD

Beth Johnson, RPh
Jameson Rice, PharmD
Keith Tolman, MD

Committee Members Excused:

Ellie Brownstein, MD

Elizabeth Young, PharmD

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, PharmD
Merelynn Berrett, RN
Heather Santacruz

Chad Hope, PharmD
Megan Schlappi, CPhT

University of Utah Drug Regimen Review Center Staff Present:

Melissa Archer, PharmD
Joanne Lafleur

Vicki Frydrych, UofU

Other Individuals Present:

Mark German, Novartis
Lori Blackman, Pfizer
Greg Powell, PA-C
James Gausted, Purdue Pharma
Robert Nohavec, UofU Health Plans
Lynsey Spence, SAO
Charissa Anne, Johnson & Johnson
David Pulsipher, SAO
Thomas Nguyen, Select Health

Alan Bailey, Pfizer
Cody Ball, Select Health
Rupa Shah, Purdue Pharma
Elizabeth Ariano, Indivior
Kylan Brown, SAO
Nick Purse, SAO
Jacob Saunders, UUSOM
Ryan Marcum, Pharmacy Student

Meeting conducted by: Clinton Sheffield, MD

1. **Welcome & Housekeeping:** Clinton Sheffield opened the meeting and reminded everyone to sign in. Bryan Larson let the board know that this meeting was a re-review of a topic last discussed in 2007. Changes to the motion made in 2007 have since occurred. He also let the board know that Utah Medicaid would start reviewing mental health drugs for inclusion on the PDL beginning next month.
2. **Review and Approval of February Minutes:** Keith Tolman made a motion to

approve the minutes from February. Clinton Sheffield seconded the motion. All in favor.

3. **Drug Utilization Review (DUR) Board update:** The DUR board met to review Hepatitis C drugs. Each ACO presented their criteria and rationale for asking Utah Medicaid to change their current criteria. The current PA criteria were changed.
4. **Long Acting Opioids:** Vicki Frydrych presented a review of the Long Acting Opioids. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
5. **Public Comment:**
 - a. Greg F. Powell, PA-C- Greg Powell asked the board to consider putting an abuse deterring formulation on the PDL to help give him the tools to try and stop opioid abuse.
 - b. Lori Blackner, Pfizer- Lori Blackner presented information regarding the drug Embeda. She asked the board to consider adding it as preferred on the PDL. She also stated that opioid induced deaths have risen 14% in Utah from the previous year.
 - c. Rupa Shah, Purdue Pharma L.P- Rupa Shah presented information about the drug Butrans. She stated that Butrans is currently the only transdermal buprenorphine product on the market.
6. **Board Discussion**
 - a. Clinton Sheffield asked what the difference was between Kadian and Morphine ER tablets. Vicki Frydrych told him that Kadian contains an abuse deterrent. Greg Powell stated that Kadian also has a longer onset of effect, which can help deter abuse.
 - b. Beth Johnson noted that some States, like Utah, with high opioid abuse are trying harder to follow the FDA's suggestion of prescribing these newer medications with abuse deterrents. She stated that opioid abuse is a huge epidemic, and the board as a professional group really needs to look at the whole picture and see the negative effects of opiates.
 - c. Chad Hope stated that a lot of the issues the board was discussing were actually issues that the DUR board should be looking at instead.
 - d. Keith Tolman made a motion to refer all opioids for chronic, non-cancer patients to the DUR board. Clinton Sheffield seconded. All in favor.
 - e. The board noted that it was hard to tell which of the new drugs were better than others, or if they were any more or less effective than older formulations. Vicki Frydrych told them that each new drug is a little different, but ultimately they appear to be equally effective.
 - f. Clinton Sheffield made a motion that all agents are equally effective and that at least one abuse deterrent and one transdermal formulation should be preferred on the PDL. Methadone, however, is not equally safe and should be non-preferred. Bryan Larson seconded. All in favor.
7. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States Medicaid programs.

8. Meeting Adjourned

9. Next meeting is scheduled for April 21st, 2016. Atypical Antipsychotics (oral and injectable) will be discussed.

Minutes prepared by Megan Schlappi, CPhT

Recording available upon request, send email to medicaidpharmacy@utah.gov